50359
Voglibose
≥97.0% (TLC)
别名:
3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol, N-(1,3-Dihydroxyprop-2-yl)valiolamine
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C10H21NO7
化学文摘社编号:
分子量:
267.28
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12352201
MDL number:
biological source
synthetic
Quality Level
assay
≥97.0% (TLC)
form
powder
color
white
storage temp.
−20°C
SMILES string
OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
InChI
1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
InChI key
FZNCGRZWXLXZSZ-CIQUZCHMSA-N
Gene Information
human ... GAA(2548), MGAM(8972), MGAM2(93432), SI(6476)
Application
Voglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway.
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
Other Notes
To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Devasier Bennet et al.
International journal of nanomedicine, 7, 3399-3419 (2012-08-14)
Antioxidant (quercetin) and hypoglycemic (voglibose) drug-loaded poly-D,L-lactideco-glycolide nanoparticles were successfully synthesized using the solvent evaporation method. The dual drug-loaded nanoparticles were incorporated into a scaffold film using a solvent casting method, creating a controlled transdermal drug-delivery system. Key features of
Xiaolong Chen et al.
Current medicinal chemistry, 13(1), 109-116 (2006-02-07)
The number of people with diabetes is expected to rise from the current estimated 150 million to 220 million in 2010 and 300 million in 2025, and 90% is Type 2 diabetes or non-insulin dependent diabetes mellitus (NIDDM). Voglibose, one
Y Iwamoto et al.
Diabetes, obesity & metabolism, 12(7), 613-622 (2010-07-02)
To compare the efficacy and safety of sitagliptin (a dipeptidyl peptidase-4 inhibitor) and voglibose (an alpha-glucosidase inhibitor) monotherapy in Japanese patients with type 2 diabetes who have inadequate glycaemic control (HbA1c > or =6.5% and <10.0%) on diet and exercise.
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 50359-10MG | 04061832422794 |